Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Emilien, G; Durlach, C; Aveaux, D; Maloteaux, JM
   Dopamine D-3 agonists
   EXPERT OPINION ON THERAPEUTIC PATENTS
   
   G. Emilien et al., "Dopamine D-3 agonists", EXPERT OP T, 11(11), 2001, pp. 1713-1728
2. Emilien, G; Misteli, C; Aveaux, D; Maloteaux, JM
   Life after sequencing
   TRENDS IN BIOTECHNOLOGY
   
   G. Emilien et al., "Life after sequencing", TRENDS BIOT, 19(7), 2001, pp. 246-246
3. Emilien, G; Ponchon, M; Caldas, C; Isacson, O; Maloteaux, JM
   Impact of genomics on drug discovery and clinical medicine
   QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS
   
   G. Emilien et al., "Impact of genomics on drug discovery and clinical medicine", QJM-MON J A, 93(7), 2000, pp. 391-423
4. Emilien, G; Penasse, C; Charles, G; Martin, D; Lasseaux, L; Waltregny, A
   Post-traumatic stress disorder: Hypotheses from clinical neuropsychology and psychopharmacology research
   INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
   
   G. Emilien et al., "Post-traumatic stress disorder: Hypotheses from clinical neuropsychology and psychopharmacology research", INT J PSYC, 4(1), 2000, pp. 3-18
5. Hedner, J; Yaeche, R; Emilien, G; Farr, I; Salinas, E
   Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia
   INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY
   
   J. Hedner et al., "Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia", INT J GER P, 15(8), 2000, pp. 704-712
6. Emilien, G; van Meurs, W; Maloteaux, JM
   The dose-response relationship in Phase I clinical trials and beyond: use,meaning, and assessment
   PHARMACOLOGY & THERAPEUTICS
   
   G. Emilien et al., "The dose-response relationship in Phase I clinical trials and beyond: use,meaning, and assessment", PHARM THERA, 88(1), 2000, pp. 33-58
7. Emilien, G; Maloteaux, JM; Penasse, C; Goodeve, A; Casimir, C
   Haemophilias: advances towards genetic engineering replacement therapy
   CLINICAL AND LABORATORY HAEMATOLOGY
   
   G. Emilien et al., "Haemophilias: advances towards genetic engineering replacement therapy", CLIN LAB H, 22(6), 2000, pp. 313-323
8. Emilien, G; Beyreuther, K; Masters, CL; Maloteaux, JM
   Prospects for pharmacological intervention in Alzheimer disease
   ARCHIVES OF NEUROLOGY
   
   G. Emilien et al., "Prospects for pharmacological intervention in Alzheimer disease", ARCH NEUROL, 57(4), 2000, pp. 454-459
9. Emilien, G; Maloteaux, JM; Beyreuther, K; Masters, CL
   Alzheimer disease - Mouse models pave the way for therapeutic opportunities
   ARCHIVES OF NEUROLOGY
   
   G. Emilien et al., "Alzheimer disease - Mouse models pave the way for therapeutic opportunities", ARCH NEUROL, 57(2), 2000, pp. 176-181
10. Emilien, G; Maloteaux, JM
    Circadian system and sleep anomaly in depression
    IRISH JOURNAL OF PSYCHOLOGICAL MEDICINE
    
    G. Emilien e J.M. Maloteaux, "Circadian system and sleep anomaly in depression", IRIS J PS M, 16(1), 1999, pp. 18-23
11. Emilien, G; Maloteaux, JM; Geurts, M; Hoogenberg, K; Cragg, S
    Dopamine receptors - physiological understanding to therapeutic intervention potential
    PHARMACOLOGY & THERAPEUTICS
    
    G. Emilien et al., "Dopamine receptors - physiological understanding to therapeutic intervention potential", PHARM THERA, 84(2), 1999, pp. 133-156
12. Emilien, G; Maloteaux, JM; Ponchon, M
    Pharmacological management of diabetes: Recent progress and future perspective in daily drug treatment
    PHARMACOLOGY & THERAPEUTICS
    
    G. Emilien et al., "Pharmacological management of diabetes: Recent progress and future perspective in daily drug treatment", PHARM THERA, 81(1), 1999, pp. 37-51
13. Elie, R; Ruther, E; Farr, I; Emilien, G; Salinas, E
    Sleep latency is shortened during 4 weeks of treatment with zaleplon a novel nonbenzodiazepine hypnotic
    JOURNAL OF CLINICAL PSYCHIATRY
    
    R. Elie et al., "Sleep latency is shortened during 4 weeks of treatment with zaleplon a novel nonbenzodiazepine hypnotic", J CLIN PSY, 60(8), 1999, pp. 536-544
14. EMILIEN G; MALOTEAUX JM
    PHARMACOLOGICAL MANAGEMENT OF EPILEPSY - MECHANISM OF ACTION, PHARMACOKINETIC DRUG-INTERACTIONS, AND NEW DRUG DISCOVERY POSSIBILITIES
    International journal of clinical pharmacology and therapeutics
    
    G. Emilien e J.M. Maloteaux, "PHARMACOLOGICAL MANAGEMENT OF EPILEPSY - MECHANISM OF ACTION, PHARMACOKINETIC DRUG-INTERACTIONS, AND NEW DRUG DISCOVERY POSSIBILITIES", International journal of clinical pharmacology and therapeutics, 36(4), 1998, pp. 181-194
15. EMILIEN G; MALOTEAUX JM; SEGHERS A; CHARLES G
    USE OF A PLACEBO IN CLINICAL-TRIALS
    European psychiatry
    
    G. Emilien et al., "USE OF A PLACEBO IN CLINICAL-TRIALS", European psychiatry, 13(5), 1998, pp. 254-263
16. EMILIEN G; MALOTEAUX JM
    CURRENT THERAPEUTIC USES AND POTENTIAL OF BETA-ADRENOCEPTOR AGONISTS AND ANTAGONISTS
    European Journal of Clinical Pharmacology
    
    G. Emilien e J.M. Maloteaux, "CURRENT THERAPEUTIC USES AND POTENTIAL OF BETA-ADRENOCEPTOR AGONISTS AND ANTAGONISTS", European Journal of Clinical Pharmacology, 53(6), 1998, pp. 389-404
17. EMILIEN G
    FUTURE EUROPEAN HEALTH-CARE - COST-CONTAINMENT, HEALTH-CARE REFORM AND SCIENTIFIC PROGRESS IN DRUG RESEARCH
    The International journal of health planning and management
    
    G. Emilien, "FUTURE EUROPEAN HEALTH-CARE - COST-CONTAINMENT, HEALTH-CARE REFORM AND SCIENTIFIC PROGRESS IN DRUG RESEARCH", The International journal of health planning and management, 12(2), 1997, pp. 81-101
18. EMILIEN G; MALOTEAUX JM; SEGHERS A; CHARLES G
    LITHIUM COMPARED TO VALPROIC ACID AND CARBAMAZEPINE IN THE TREATMENT OF MANIA - A STATISTICAL METAANALYSIS
    European neuropsychopharmacology
    
    G. Emilien et al., "LITHIUM COMPARED TO VALPROIC ACID AND CARBAMAZEPINE IN THE TREATMENT OF MANIA - A STATISTICAL METAANALYSIS", European neuropsychopharmacology, 6(3), 1996, pp. 245-252
19. EMILIEN G; MALOTEAUX JM
    LITHIUM NEUROTOXICITY AT LOW THERAPEUTIC DOSES HYPOTHESES FOR CAUSES AND MECHANISM OF ACTION FOLLOWING A RETROSPECTIVE ANALYSIS OF PUBLISHED CASE-REPORTS
    Acta neurologica belgica
    
    G. Emilien e J.M. Maloteaux, "LITHIUM NEUROTOXICITY AT LOW THERAPEUTIC DOSES HYPOTHESES FOR CAUSES AND MECHANISM OF ACTION FOLLOWING A RETROSPECTIVE ANALYSIS OF PUBLISHED CASE-REPORTS", Acta neurologica belgica, 96(4), 1996, pp. 281-293
20. EMILIEN G; WALTREGNY A
    TRAUMATIC BRAIN INJURY, COGNITIVE AND EMOTIONAL DYSFUNCTION - IMPACT OF CLINICAL NEUROPSYCHOLOGY RESEARCH
    Acta neurologica belgica
    
    G. Emilien e A. Waltregny, "TRAUMATIC BRAIN INJURY, COGNITIVE AND EMOTIONAL DYSFUNCTION - IMPACT OF CLINICAL NEUROPSYCHOLOGY RESEARCH", Acta neurologica belgica, 96(2), 1996, pp. 89-101
21. EMILIEN G; MALOTEAUX JM; SEGHERS A; CHARLES G
    LITHIUM-THERAPY IN THE TREATMENT OF MANIC-DEPRESSIVE ILLNESS - PRESENT STATUS AND FUTURE PERSPECTIVES - A CRITICAL-REVIEW
    Archives internationales de pharmacodynamie et de therapie
    
    G. Emilien et al., "LITHIUM-THERAPY IN THE TREATMENT OF MANIC-DEPRESSIVE ILLNESS - PRESENT STATUS AND FUTURE PERSPECTIVES - A CRITICAL-REVIEW", Archives internationales de pharmacodynamie et de therapie, 330(3), 1995, pp. 251-278